Abstract
With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored molecules has brought a revolution in medicinal chemistry for treating tumours caused by kinase malfunctioning. Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks. Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of molecules. Furthermore, we present the strategies for designing druggable molecules that either selectively inhibit target kinases or overcome drug resistance.
Keywords: Allosteric inhibitors, cancer, covalent inhibitors, DFG-in, DFG-out, kinase inhibitors, Type I inhibitors, Type II inhibitors, Type III inhibitors, Type IV inhibitors.
Anti-Cancer Agents in Medicinal Chemistry
Title:Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
Volume: 13 Issue: 5
Author(s): Javier Blanc, Raphael Geney and Christel Menet
Affiliation:
Keywords: Allosteric inhibitors, cancer, covalent inhibitors, DFG-in, DFG-out, kinase inhibitors, Type I inhibitors, Type II inhibitors, Type III inhibitors, Type IV inhibitors.
Abstract: With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored molecules has brought a revolution in medicinal chemistry for treating tumours caused by kinase malfunctioning. Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks. Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of molecules. Furthermore, we present the strategies for designing druggable molecules that either selectively inhibit target kinases or overcome drug resistance.
Export Options
About this article
Cite this article as:
Blanc Javier, Geney Raphael and Menet Christel, Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/1871520611313050008
DOI https://dx.doi.org/10.2174/1871520611313050008 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Biological Functions of NF-κB1 (p ) and its Potential as an Anti-Cancer Target
Current Cancer Drug Targets Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Macromolecular and Nanotechnological Modification of Camptothecin and its Analogs to Improve the Efficacy
Current Drug Discovery Technologies Thrombotic Thrombocytopenic Purpura, from the Perspectives of a Pediatrician
Current Pediatric Reviews Prebiotics: A New Hope Against Antibiotic Associated Diarrhea
Anti-Infective Agents Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis
Current Gene Therapy Meet Our Section Editor
Current Cancer Drug Targets Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Tyrosine Kinases as New Molecular Targets in Treatment of Inflammatory Disorders and Leukemia
Current Pharmaceutical Design Integrative Analysis of miRNA-mediated Competing Endogenous RNA Network Reveals the lncRNAs-mRNAs Interaction in Glioblastoma Stem Cell Differentiation
Current Bioinformatics Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation
Current Pharmaceutical Design Indoor Dust Levels of Perfluoroalkyl Substances (PFASs) and the Role of Ingestion as an Exposure Pathway: A Review
Current Organic Chemistry